Durata Therapeutics, Inc (DRTX)

[rjanderson383]

http://en.wikipedia.org/wiki/Dalbavancin

Dalbavancin has undergone a phase III clinical trial for adults with complicated skin infections, but in Dec 2007 the FDA said more data was needed before approval.[6]

On September 9, 2008, Pfizer announced that it will withdraw all marketing applications in order to conduct another Phase 3 clinical trial.[7]

Durata Therapeutics acquired the rights to dalbavancin in December 2009 and has initiated two new Phase III clinical trials for treatment of acute bacterial skin and skin structure infections.[8] Preliminary results in Dec 2012 looked good.[9]